(Q39044618)

8 September 2017

title

Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets (English)

1 reference

8 September 2017

1 reference

6

Alice Assinger

1 reference

8 September 2017

Gisela Scharbert

1

1 reference

8 September 2017

Leonore Wetzel

2

1 reference

8 September 2017

Waltraud C Schrottmaier

3

1 reference

8 September 2017

Julia B Kral

4

1 reference

8 September 2017

Thomas Weber

5

1 reference

8 September 2017

publication date

15 January 2015

1 reference

8 September 2017

1 reference

8 September 2017

volume

55

1 reference

8 September 2017

issue

6

1 reference

8 September 2017

page(s)

1320-1326

1 reference

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

8 September 2017

cites work

1 reference

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects

21 January 2018

1 reference

Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects

21 January 2018

1 reference

Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

21 January 2018

Platelet transfusions

1 reference

Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses

21 January 2018

1 reference

Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2.

21 January 2018

1 reference

Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.

21 January 2018

1 reference

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor

21 January 2018

1 reference

A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats

21 January 2018

1 reference

Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.

21 January 2018

1 reference

Normalization of platelet reactivity in clopidogrel-treated subjects

21 January 2018

1 reference

Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor.

21 January 2018

1 reference

In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation

21 January 2018

1 reference

Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/TRF.12977

1 reference

8 September 2017

1 reference